New endpoints for early-stage cancer are gaining regulatory traction
Using the standard regulatory endpoints of overall survival (OS) and progression-free survival (PFS) may not be feasible in some early-stage cancer trials due to the time it would take to reach the number of patient deaths and disease progression events to demonstrate efficacy. Novel endpoints that can offer quicker insights into the short- or long-term clinical benefits of new cancer drugs are needed, especially for early-stage cancer and immediately before (neoadjuvant) and after (adjuvant) primary treatment. This article covers three promising new endpoints.
Related Insights
Webinar
Navigating the complexities of AML drug development
Oct 30, 2024
Webinar
Advancing mRNA-based drug development and vaccine manufacturing
Jul 1, 2024
Blog
PD-1 inhibitors face scrutiny in esophageal cancer: Key takeaways for drug developers
Oct 4, 2024
Blog
Making cell and gene therapy more accessible in the treatment of solid tumors
Jun 4, 2024
Article
Q&A Project Optimus: What you need to know
Oct 11, 2022
Article
Five strategies for meeting the requirements of Project Optimus and improving the chances of approval
Nov 10, 2022
Webinar
Challenges and best practices for developing Antibody-Drug Conjugates (ADCs)
Nov 12, 2024
Blog
Navigating the Joint Clinical Assessment (JCA) implementation: An analysis of EU member states readiness, challenges and opportunities for harmonization
Jan 9, 2025
Playbook
Are you using real-world evidence?
Feb 1, 2023
Blog
Innovative modeling method could speed patient access to critical IO therapies
Jan 4, 2023
Article
Relyvrio Approval: Lessons Learned
Oct 31, 2022
Webinar
How to navigate China’s regulatory environment
Feb 15, 2023
Related Insights
Webinar
Navigating the complexities of AML drug development
Oct 30, 2024
Webinar
Advancing mRNA-based drug development and vaccine manufacturing
Jul 1, 2024
Blog
PD-1 inhibitors face scrutiny in esophageal cancer: Key takeaways for drug developers
Oct 4, 2024
Blog
Making cell and gene therapy more accessible in the treatment of solid tumors
Jun 4, 2024
Article
Q&A Project Optimus: What you need to know
Oct 11, 2022
Article
Five strategies for meeting the requirements of Project Optimus and improving the chances of approval
Nov 10, 2022
Webinar
Challenges and best practices for developing Antibody-Drug Conjugates (ADCs)
Nov 12, 2024
Blog
Navigating the Joint Clinical Assessment (JCA) implementation: An analysis of EU member states readiness, challenges and opportunities for harmonization
Jan 9, 2025
Playbook
Are you using real-world evidence?
Feb 1, 2023
Blog
Innovative modeling method could speed patient access to critical IO therapies
Jan 4, 2023
Article
Relyvrio Approval: Lessons Learned
Oct 31, 2022
Webinar
How to navigate China’s regulatory environment
Feb 15, 2023